Characterization of ovulation inhibition of a new vaginal delivery system (EVE 112, Evestra/Germany) containing etonogestrel and ethinylestradiol an open label, single centre, comparative, parallel-group study in healthy females of childbearing potential

Trial Profile

Characterization of ovulation inhibition of a new vaginal delivery system (EVE 112, Evestra/Germany) containing etonogestrel and ethinylestradiol an open label, single centre, comparative, parallel-group study in healthy females of childbearing potential

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Ethinylestradiol/etonogestrel (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Evestra
  • Most Recent Events

    • 10 Mar 2017 Status changed from recruiting to completed.
    • 16 Apr 2016 Planned number of patients changed from 50 to 88.
    • 14 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top